軟部肉腫の世界市場規模調査＆予測、治療別、投与経路別、エンドユーザー別、地域別分析、2023-2030年

軟部肉腫は、筋肉、腱、脂肪、神経、血管、結合組織などの体の軟部組織に発生するがんの一種です。

体の軟部組織にしこりや腫れがある場合は、軟部肉腫の兆候です。軟部肉腫が発生する部位は体内の様々な場所にあり、生検によって特定されます。世界市場の成長は、新規治療法の採用の増加、個別化医療への注目の高まり、人口の増加、医療費の増加などの要因に加え、有利な償還政策が後押ししています。

また、がんの発生件数の増加が、世界の市場成長の触媒として作用しています。世界保健機関（WHO）によると、2020年には世界で約1,930万件の新たながん患者が記録されたと推定されており、今後増加し、2040年には3,030万件に達する可能性が高いと予測されています。したがって、これらの前述の要因が、推定期間中の軟部肉腫市場の成長を促進しています。さらに、診断や治療法の進歩、研究開発への投資の増加は、予測期間中にさまざまな有利な機会をもたらしています。しかし、治療費の高さと軟部肉腫治療薬の副作用が、2023年から2030年の予測期間を通じて市場成長を妨げています。

軟部肉腫の世界市場調査において考慮された主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、標的治療への需要の急増、個別化医療への注目の高まり、確立されたヘルスケア施設の存在により、2022年の市場を独占しました。一方、アジア太平洋は、軟部肉腫の有病率の上昇、医療費の増加、研究開発への投資の増加などの要因から、予測期間中に最も高いCAGRで成長すると予想されます。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を定義し、今後数年間の値を予測することです。本レポートは、調査対象国において、業界の質的・量的な側面を取り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

• マーケットスナップショット
• 世界市場・セグメント別市場推計・予測、2020-2030年
  • 軟部肉腫の市場：地域別、2020年～2030年
  • 軟部肉腫の市場：治療別、2020-2030年
  • 軟部肉腫市場：投与経路別、2020年～2030年
  • 軟部肉腫市場：エンドユーザー別、2020年～2030年
• 主な動向
• 調査手法
• 調査の前提条件

第2章 軟部肉腫の世界市場の定義と範囲

• 調査目的
• 市場の定義とスコープ
  • 産業の進化
  • 本調査の対象範囲
• 調査対象年
• 通貨換算レート

第3章 軟部肉腫の世界市場力学

• 軟部肉腫の市場インパクト分析（2020年～2030年）
  • 市場促進要因
    • 新規治療法の採用が増加
    • がん罹患率の上昇
  • 市場の課題
    • 治療費の高騰
    • 軟部肉腫治療薬の副作用
  • 市場機会
    • 診断法および治療法における進歩の高まり
    • 研究開発への投資の増加

第4章 軟部肉腫の世界市場産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォースインパクト分析
• PEST分析
  • 政治的
  • 経済的
  • 社会的
  • 技術的
  • 環境
  • 法律
• トップ投資機会
• 主要成功戦略
• COVID-19影響度分析
• 破壊的動向
• 業界専門家の視点
• アナリストの提言と結論

第5章 軟部肉腫の世界市場：治療別

• 市場スナップショット
• 軟部肉腫の世界市場：治療別、実績・ポテンシャル分析
• 軟部肉腫の世界市場、治療別推定・予測2020～2030年
• 軟部肉腫の市場、サブセグメント別分析
  • 標的療法
  • 化学療法
  • 抗アンジオジェネシス薬
  • 放射線療法

第6章 軟部肉腫の世界市場：投与経路別

• 市場スナップショット
• 軟部肉腫の世界市場：投与経路別、実績・ポテンシャル分析
• 軟部肉腫の世界市場、投与経路別推定・予測2020～2030年
• 軟部肉腫の市場、サブセグメント別分析
  • 経口剤
  • 非経口剤
  • その他

第7章 軟部肉腫の世界市場：エンドユーザー別

• 市場スナップショット
• 軟部肉腫の世界市場：エンドユーザー別、実績・ポテンシャル分析
• 軟部肉腫の世界市場、エンドユーザー別推定・予測2020-2030
• 軟部肉腫の市場、サブセグメント別分析
  • 病院
  • ホームケア
  • スペシャリティセンター
  • その他

第8章 軟部肉腫の世界市場：地域別分析

• 上位の主要国
• 上位新興国
• 軟部肉腫の市場、地域別マーケットスナップショット
• 北米
  • 米国
    • 治療別の推定・予測、2020-2030年
    • 投与経路別の推定・予測、2020-2030年
    • エンドユーザー別の推定・予測、2020-2030年
  • カナダ
• 欧州軟部肉腫市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋軟部肉腫市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカの軟部肉腫市場スナップショット
  • ブラジル
  • メキシコ
• 中東・アフリカ地域
  • サウジアラビア
  • 南アフリカ
  • その他中東とアフリカ

第9章 競合情報

• 主要企業のSWOT分析
  • 企業1
  • 会社2
  • 3社
• トップ市場戦略
• 企業プロファイル
  • F. Hoffmann-La Roche Ltd.（Switzerland）
    • 主要情報
    • 概要
    • 財務情報（データの入手が可能な場合のみ）
    • 製品概要
    • 最近の動向
  • Mylan N.V.（U.S.）
  • Teva Pharmaceutical Industries Ltd.（Israel）
  • Sanofi（France）
  • Pfizer Inc.（U.S.）
  • GSK plc（U.K.）
  • Novartis AG（Switzerland）
  • Bayer AG（Germany）
  • Merck & Co., Inc.（U.S.）
  • Sun Pharmaceutical Industries Ltd.（India）

第10章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • バリデーション
  • 出版
• 調査の特徴
• 調査の前提条件

LIST OF TABLES

• TABLE 1. Global Soft Tissue Sarcoma Market, report scope
• TABLE 2. Global Soft Tissue Sarcoma Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3. Global Soft Tissue Sarcoma Market estimates & forecasts by Treatment 2020-2030 (USD Billion)
• TABLE 4. Global Soft Tissue Sarcoma Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
• TABLE 5. Global Soft Tissue Sarcoma Market estimates & forecasts by End-users 2020-2030 (USD Billion)
• TABLE 6. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 7. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14. Global Soft Tissue Sarcoma Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15. Global Soft Tissue Sarcoma Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16. U.S. Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 17. U.S. Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 18. U.S. Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 19. Canada Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 20. Canada Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 21. Canada Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 22. UK Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 23. UK Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 24. UK Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 25. Germany Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 26. Germany Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 27. Germany Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 28. France Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 29. France Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 30. France Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 31. Italy Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 32. Italy Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 33. Italy Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 34. Spain Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 35. Spain Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 36. Spain Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 37. RoE Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 38. RoE Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 39. RoE Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 40. China Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 41. China Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 42. China Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 43. India Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 44. India Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 45. India Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 46. Japan Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 47. Japan Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 48. Japan Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 49. South Korea Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 50. South Korea Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 51. South Korea Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 52. Australia Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 53. Australia Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 54. Australia Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 55. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 56. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 57. RoAPAC Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 58. Brazil Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 59. Brazil Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 60. Brazil Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 61. Mexico Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 62. Mexico Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 63. Mexico Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 64. RoLA Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 65. RoLA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 66. RoLA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 67. Saudi Arabia Soft Tissue Sarcoma Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 68. South Africa Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 69. RoMEA Soft Tissue Sarcoma Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 70. List of secondary sources, used in the study of global Soft Tissue Sarcoma Market
• TABLE 71. List of primary sources, used in the study of global Soft Tissue Sarcoma Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

• FIG 1. Global Soft Tissue Sarcoma Market, research methodology
• FIG 2. Global Soft Tissue Sarcoma Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Soft Tissue Sarcoma Market, key trends 2022
• FIG 5. Global Soft Tissue Sarcoma Market, growth prospects 2023-2030
• FIG 6. Global Soft Tissue Sarcoma Market, porters 5 force model
• FIG 7. Global Soft Tissue Sarcoma Market, pest analysis
• FIG 8. Global Soft Tissue Sarcoma Market, value chain analysis
• FIG 9. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
• FIG 10. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
• FIG 11. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
• FIG 12. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
• FIG 13. Global Soft Tissue Sarcoma Market by segment, 2020 & 2030 (USD Billion)
• FIG 14. Global Soft Tissue Sarcoma Market, regional snapshot 2020 & 2030
• FIG 15. North America Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
• FIG 16. Europe Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
• FIG 17. Asia pacific Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
• FIG 18. Latin America Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)
• FIG 19. Middle East & Africa Soft Tissue Sarcoma Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Soft Tissue Sarcoma Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Soft tissue sarcoma is a type of cancer that originates in the soft tissues of the body, such as muscles, tendons, fat, nerves, blood vessels, and connective tissues. A lump or swelling in a body's soft tissue is an indication of soft tissue sarcoma. There are many different locations on the body where soft tissue sarcomas develop, which is identified through biopsy. The global market growth is driven by factors such as the rising adoption of novel therapies, growing focus on personalized medicine, escalating population, and increasing healthcare expenditure, coupled with favorable reimbursement policies.

In addition, the surge in the incidences of cancer is acting as a catalyzing factor for market growth across the globe. According to the World Health Organization, in 2020, it was estimated that around 19.3 million new cancer cases were recorded globally, which is projected to increase and likely to reach 30.3 million cases by the year 2040. Thus, these aforementioned factors are propelling the growth of the soft tissue sarcoma market during the estimated period. Moreover, the rising advancements in diagnostics and treatment options, as well as increasing investments in research and development is presenting various lucrative opportunities over the forecasting years. However, the high cost of treatments and the side effects of soft tissue sarcoma drugs are hampering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Soft Tissue Sarcoma Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the surging demand for targeted therapies, rising focus on personalized medicine, and the presence of well-established healthcare facilities. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the rising prevalence of soft tissue sarcoma, increasing healthcare expenditure, and growing investments in research and development.

Major market players included in this report are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)

Recent Developments in the Market:

• In 2019, Pfizer announced that Vitrakvi (larotrectinib) had received European Commission approval for the treatment of advanced soft tissue sarcoma. Vitrakvi - a targeted medication is available to patients whose tumours have a particular genetic mutation.
• In 2019, Johnson & Johnson declared that the US Food and Drug Administration had authorized JNJ-4528 as a medication for the management of relapsed or refractory multiple myeloma. JNJ-4528 is a CAR-T cell therapy that is developed for use in the treatment of several malignancies, including some types of sarcomas.

Global Soft Tissue Sarcoma Market Report Scope:

• Historical Data: - 2020 - 2021
• Base Year for Estimation: - 2022
• Forecast period: - 2023-2030
• Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: - Treatment, Route of Administration, End-users, Region
• Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Treatment:

• Targeted Therapy
• Chemotherapy
• Anti-Angiogenesis Drugs
• Radiation Therapy

By Route of Administration:

• Oral
• Parenteral
• Others

By End-users:

• Hospitals
• Homecare
• Speciality Centres
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Soft Tissue Sarcoma Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Soft Tissue Sarcoma Market, by Treatment, 2020-2030 (USD Billion)
  • 1.2.3. Soft Tissue Sarcoma Market, by Route of Administration, 2020-2030 (USD Billion)
  • 1.2.4. Soft Tissue Sarcoma Market, by End-users, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Soft Tissue Sarcoma Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Soft Tissue Sarcoma Market Dynamics

• 3.1. Soft Tissue Sarcoma Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising adoption of novel therapies
    • 3.1.1.2. Surge in the incidences of cancer
  • 3.1.2. Market Challenges
    • 3.1.2.1. High cost of treatments
    • 3.1.2.2. Side effects of soft tissue sarcoma drugs
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising advancements in diagnostics and treatment options
    • 3.1.3.2. Increasing investments in research and development

Chapter 4. Global Soft Tissue Sarcoma Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Soft Tissue Sarcoma Market, by Treatment

• 5.1. Market Snapshot
• 5.2. Global Soft Tissue Sarcoma Market by Treatment, Performance - Potential Analysis
• 5.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by Treatment 2020-2030 (USD Billion)
• 5.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
  • 5.4.1. Targeted Therapy
  • 5.4.2. Chemotherapy
  • 5.4.3. Anti-Angiogenesis Drugs
  • 5.4.4. Radiation Therapy

Chapter 6. Global Soft Tissue Sarcoma Market, by Route of Administration

• 6.1. Market Snapshot
• 6.2. Global Soft Tissue Sarcoma Market by Route of Administration, Performance - Potential Analysis
• 6.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
• 6.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
  • 6.4.1. Oral
  • 6.4.2. Parenteral
  • 6.4.3. Others

Chapter 7. Global Soft Tissue Sarcoma Market, by End-users

• 7.1. Market Snapshot
• 7.2. Global Soft Tissue Sarcoma Market by End-users, Performance - Potential Analysis
• 7.3. Global Soft Tissue Sarcoma Market Estimates & Forecasts by End-users 2020-2030 (USD Billion)
• 7.4. Soft Tissue Sarcoma Market, Sub Segment Analysis
  • 7.4.1. Hospitals
  • 7.4.2. Homecare
  • 7.4.3. Speciality Centres
  • 7.4.4. Others

Chapter 8. Global Soft Tissue Sarcoma Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Soft Tissue Sarcoma Market, Regional Market Snapshot
• 8.4. North America Soft Tissue Sarcoma Market
  • 8.4.1. U.S. Soft Tissue Sarcoma Market
    • 8.4.1.1. Treatment breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. End-users breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Soft Tissue Sarcoma Market
• 8.5. Europe Soft Tissue Sarcoma Market Snapshot
  • 8.5.1. U.K. Soft Tissue Sarcoma Market
  • 8.5.2. Germany Soft Tissue Sarcoma Market
  • 8.5.3. France Soft Tissue Sarcoma Market
  • 8.5.4. Spain Soft Tissue Sarcoma Market
  • 8.5.5. Italy Soft Tissue Sarcoma Market
  • 8.5.6. Rest of Europe Soft Tissue Sarcoma Market
• 8.6. Asia-Pacific Soft Tissue Sarcoma Market Snapshot
  • 8.6.1. China Soft Tissue Sarcoma Market
  • 8.6.2. India Soft Tissue Sarcoma Market
  • 8.6.3. Japan Soft Tissue Sarcoma Market
  • 8.6.4. Australia Soft Tissue Sarcoma Market
  • 8.6.5. South Korea Soft Tissue Sarcoma Market
  • 8.6.6. Rest of Asia Pacific Soft Tissue Sarcoma Market
• 8.7. Latin America Soft Tissue Sarcoma Market Snapshot
  • 8.7.1. Brazil Soft Tissue Sarcoma Market
  • 8.7.2. Mexico Soft Tissue Sarcoma Market
• 8.8. Middle East & Africa Soft Tissue Sarcoma Market
  • 8.8.1. Saudi Arabia Soft Tissue Sarcoma Market
  • 8.8.2. South Africa Soft Tissue Sarcoma Market
  • 8.8.3. Rest of Middle East & Africa Soft Tissue Sarcoma Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. F. Hoffmann-La Roche Ltd. (Switzerland)
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Mylan N.V. (U.S.)
  • 9.3.3. Teva Pharmaceutical Industries Ltd. (Israel)
  • 9.3.4. Sanofi (France)
  • 9.3.5. Pfizer Inc. (U.S.)
  • 9.3.6. GSK plc (U.K.)
  • 9.3.7. Novartis AG (Switzerland)
  • 9.3.8. Bayer AG (Germany)
  • 9.3.9. Merck & Co., Inc. (U.S.)
  • 9.3.10. Sun Pharmaceutical Industries Ltd. (India)

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption